Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 305-316

  Miyoshi, Seigo ^a   Hamada, Hironobu ^a,b   Ito, Ryoji ^a   Katayama, Hitoshi ^a   Irifune, Kazunori ^a   Suwaki, Toshimitsu ^c   Nakanishi, Norihiko ^d   Kanematsu, Takanori ^e   Dote, Kentaro ^f   Aibiki, Mayuki ^g   Okura, Takafumi ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Sumitomo Besshi Hospital   (Japan)

^d EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e MATSUYAMA RED CROSS HOSPITAL   (Japan)

^f EHIME UNIVERSITY HOSPITAL   (Japan)

^g EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Neutrophil elastase; Procalcitonin; Systemic inflammatory response syndrome; Ventilator free days

Indexed keywords

LEUKOCYTE ELASTASE; PROCALCITONIN; SIVELESTAT;

ACUTE LUNG INJURY; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME;

NEUTROPHIL ELASTASE; PROCALCITONIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENTILATOR-FREE DAYS;

ACUTE LUNG INJURY; AGED; CALCITONIN; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; OXYGEN; PROTEIN PRECURSORS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RETROSPECTIVE STUDIES; SEPSIS; SERINE PROTEINASE INHIBITORS; SULFONAMIDES; SURVIVAL RATE;

EID: 84876219503     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42004     Document Type: Article

References (37)

1. Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011; 24(5):549-554.
2. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-1349.
3. Janoff A, White R, Carp H, Harel S, Dearing R, Lee D. Lung injury induced by leukocytic proteases. Am J Pathol. 1979;97(1): 111-136.
4. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance. Am Rev Respir Dis. 1986;133(2):218-225.
5. Idell S, Kucich U, Fein A, et al. Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis. 1985;132(5):1098-1105.
6. Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(5):1428-1433.
7. Petty TL. Protease mechanisms in the pathogenesis of acute lung injury. Ann N Y Acad Sci. 1991;624:267-277.
8. Ueno H, Hirasawa H, Oda S, Shiga H, Nakanishi K, Matsuda K. Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure. Crit Care Med. 2002;30(10):2242-2248.
9. McGill SN, Ahmed NA, Christou NV. Endothelial cells: role in infection and inflammation. World J Surg. 1998;22(2):171-178.
10. Russell JA. Management of sepsis. N Engl J Med. 2006;355(16): 1699-1713.
11. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991;177(2):814-820.
12. Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Yoshikawa S, Sugimotoa K. Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccharide-induced acute lung inflammation in hamsters. Shock. 2006;26(1):95-98.
13. Tamakuma S, Ogawa M, Aikawa N, et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 2004;17(5):271-279.
14. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32(8):1695-1702.
15. Endo S, Sato N, Yaegashi Y, et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Res Commun Mol Pathol Pharmacol. 2006;119(1-6):53-65.
16. Tsuboko Y, Takeda S, Mii S, et al. Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis. Drug Des Devel Ther. 2012;6:273-278.
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
18. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824.
19. Gando S, Iba T, Eguchi Y, et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625-631.
20. Singh RK, Baronia AK, Sahoo JN, et al. Prospective comparison of new Japanese Association for Acute Medicine (JAAM) DIC and International Society of Thrombosis and Hemostasis (ISTH) DIC score in critically ill septic patients. Thromb Res. 2012;129(4):e119-e125.
21. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250-1256.
22. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-1758.
23. Jegal Y, Lee SI, Lee KH, et al. The clinical efficacy of GOCA scoring system in patients with acute respiratory distress syndrome. J Korean Med Sci. 2008;23(3):383-389.
24. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301-1308.
25. Delèvaux I, André M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis. 2003;62(4): 337-340.
26. Hayakawa M, Katabami K, Wada T, et al. Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock. 2010;33(1):14-18.
27. Tsalik EL, Jaggers LB, Glickman SW, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2011;43(1):97-106.
28. Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta. 2005;351(1-2):17-29.
29. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737-1741.
30. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996-2003.
31. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578-5584.
32. Suda K, Takeuchi H, Hagiwara T, et al. Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock. 2010; 33(5):526-531.
33. Lin X, Yang H, Sakuragi T, et al. Alpha-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol. 2005;289(4):L583-L590.
34. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251.
35. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165(6): 2950-2954.
36. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1in inflammation and sepsis. J Intern Med. 2004;255(3):320-331.
37. Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170(12):1310-1316.